Science
A collection of resources to understand the science behind biosimilars.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
ESMO’s position is that biosimilars present a necessary and timely opportunity as they can positively impact the financial sustainability of healthcare systems while improving access to medicines for patients. Moreover, biosimilars could, in part, help address economic challenges that healthcare decision-makers are confronted with.
It is therefore important that all key stakeholders - including prescribers, pharmacists, nurses, patients, reimbursing bodies and manufacturers - understand the complexities of biosimilars and ensure that patients are being prescribed the safest and most efficacious treatment possible.
A collection of resources to understand the science behind biosimilars.
ESMO education material to help stakeholders to better understand biosimilars.
Visit this section to understand how the EMA, the US FDA, and the WHO regulate biosimilars.
A series of resources produced by ESMO and independent sources to address patient concerns regarding biosimilars.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.